|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
90,000,000 |
Market
Cap: |
1.70(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.88 - $18.88 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Latham John A |
Chief Scientific Officer |
|
2015-03-30 |
4 |
OE |
$0.39 |
$5,583 |
D/D |
14,500 |
223,488 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-03-02 |
4 |
AS |
$26.25 |
$102,357 |
D/D |
(3,900) |
0 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-03-02 |
4 |
OE |
$0.39 |
$1,502 |
D/D |
3,900 |
3,900 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-03-02 |
4 |
AS |
$26.26 |
$119,340 |
D/D |
(4,545) |
208,988 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-03-02 |
4 |
OE |
$0.39 |
$1,750 |
D/D |
4,545 |
213,533 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-01-27 |
4 |
AS |
$28.27 |
$33,921 |
D/D |
(1,200) |
0 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-01-27 |
4 |
OE |
$0.39 |
$462 |
D/D |
1,200 |
1,200 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-01-27 |
4 |
AS |
$28.73 |
$205,278 |
D/D |
(7,145) |
208,988 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-01-27 |
4 |
OE |
$0.39 |
$2,751 |
D/D |
7,145 |
216,133 |
|
- |
|
Litton Mark James |
Chief Business Officer |
|
2015-01-27 |
4 |
AS |
$28.52 |
$65,602 |
D/D |
(2,300) |
81,859 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2015-01-27 |
4 |
AS |
$28.71 |
$1,825,165 |
D/D |
(63,578) |
109,921 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-01-26 |
4 |
AS |
$27.89 |
$75,316 |
D/D |
(2,700) |
0 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2015-01-26 |
4 |
OE |
$0.39 |
$1,040 |
D/D |
2,700 |
2,700 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-01-26 |
4 |
AS |
$27.98 |
$221,008 |
D/D |
(7,900) |
208,988 |
|
- |
|
Latham John A |
Chief Scientific Officer |
|
2015-01-26 |
4 |
OE |
$0.39 |
$3,042 |
D/D |
7,900 |
216,888 |
|
- |
|
Litton Mark James |
Chief Business Officer |
|
2015-01-26 |
4 |
AS |
$28.03 |
$145,732 |
D/D |
(5,200) |
84,159 |
|
- |
|
Schatzman Randall C |
President and CEO |
|
2015-01-26 |
4 |
AS |
$27.93 |
$1,017,234 |
D/D |
(36,422) |
173,499 |
|
- |
|
Benedict Larry |
Sr. VP Finance |
|
2014-11-28 |
4 |
A |
$8.50 |
$5,636 |
D/D |
663 |
663 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2014-11-24 |
4 |
S |
$16.91 |
$153,735 |
D/D |
(9,090) |
0 |
|
- |
|
Smith Jeffrey T L |
Sr. VP Translational Medicine |
|
2014-11-21 |
4 |
S |
$15.71 |
$314,118 |
D/D |
(20,000) |
9,090 |
|
- |
|
Litton Mark James |
Chief Business Officer |
|
2014-11-20 |
4 |
S |
$15.63 |
$469,011 |
D/D |
(30,000) |
88,484 |
|
- |
|
Davidson Aaron |
Director |
|
2014-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
2,581,976 |
516,395 |
|
- |
|
H.i.g. Ventures - Alder, Llc |
10% Owner |
|
2014-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,581,976 |
516,395 |
|
- |
|
Siegall Clay B |
Director |
|
2014-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
24,444 |
24,444 |
|
- |
|
Ventures West 8 Limited Partnership |
10% Owner |
|
2014-05-13 |
4 |
B |
$10.00 |
$2,500,000 |
D/D |
250,000 |
3,469,528 |
2.45 |
- |
|
296 Records found
|
|
Page 11 of 12 |
|
|